30246-33-4

• 常用中文名：7-氨基-3-[(2-甲基-1,3,4-噻二唑-5-基硫基)甲基]-3-头孢烯-4-甲酸
• 常用英文名：7-TDA
• CAS号：30246-33-4
• 分子式：C₁₁H₁₂N₄O₃S₃
• 分子量：344.433
• 发布时间：2019-02-15 18:11:41
• 更新时间：2026-07-12 20:31:43

名称

• 中文名: 7-氨基-3-{[(5-甲基-1,3,4-噻二唑-2-基)硫]甲基}头孢霉素烷酸
• 英文名: 7-amino-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]cephalosphoranic acid
• 中文别名: 唑林钠A; (6R,7R)-7-氨基-3-(((5-甲基-1,3,4-噻二唑-2-基)硫基)甲基)-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸(头孢唑啉杂质); 头孢唑林杂质A; 化合物 (6R,7R)-7-AMINO-3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CBOXYLIC ACID; 7-氨基-3-{[(5-甲基-1,3,4-噻二唑-2-基)硫]甲基}-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢唑啉钠有关杂质A; 头孢唑林/头孢西酮母核; 头孢唑林杂质-A; 头孢唑林杂质K; 7-氨基-3-(((5-甲基-1,3,4-噻二唑-2-基)硫代)甲基)头孢烷酸; 头孢唑啉母核; 头孢唑啉母核(7-TDA); 头孢唑林钠杂质A(6R,7R)-7-氨基-3-[[(5-甲基-1,3,4-噻二唑-2-基)硫基]甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢西酮中间体,头孢西酮母核 (7-TDA); 头孢西酮母核(7-TDA); (6R,7R)-7-氨基-3-(((5-甲基-1,3,4-噻二唑-2-基)硫基)甲基)-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢唑林钠杂质A（6R，7R）-7-氨基-3-[[（5-甲基-1，3，4-噻二唑-2-基）硫基]甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢唑啉杂质7 CRS(头孢唑啉杂质A CRS); 头孢唑林钠杂质A; 头孢唑啉杂质K; 头孢西酮母核; 头孢唑啉杂质7(头孢唑啉杂质A); 头孢唑啉母核/头孢西酮母核/TDA/7-TDA/7-ZACA; 头孢唑啉杂质A
• 英文别名: Cefazolin Impurity -A; (6R,7R)-7-amino-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; (6R,7R)-7-amino-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; (6R)-7α-Amino-3-(5-methyl-1,3,4-thiadiazol-2-ylthiomethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; 7-AMINO-3-[(5-METHYL-1,3,4-THIADIAZOL-2-YL)THIOMETHYL]CHALOSPHORANIC ACID; (7r)-7-amino-3[(5-methyl-1,3,4-thiadiazole-2-yl)thiomethyl]-3-chem-4-cboxylic acid; (7r)-7-amino-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-3-chem-4-cboxylicacid; 7-ammonio-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylate; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylicacid, 7-amino-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-, (6R,7R); Cefazolin EP Impurity A; 7-Amino-3-[(2-methyl-1,3,4-thiadiazol-5-ylthio)methyl]-3-chem-4-cboxylic acid; Cefazolin Impurity A; (6R)-7t-amino-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-amino-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; TDA; Pent nucleus of cefazedone (7-TDA); 3,5-Dichloro-4-hydroxypyridine，7-Amino-3-[(5-methyl-1,3,4-thiadiazol- 2-ylthio)methyl]-3-chem-4- cboxylic Acid; Cefazolin Impurity K; 3-[(2-methyl-1,3,4-thiadiazol-5-ylthio)methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7r)-7-amino-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-3-cephem-4-carboxylicacid; (6R-trans)-7-amino-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]Methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; Cefazolin Impurity 7(Cefazolin Impurity A); (7r)-7-amino-3[(5-methyl-1,3,4-thiadiazole-2-yl)thiomethyl]-3-cephem-4-carboxylic acid; 7-amino-3-(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid; (6R-trans)-7-amino-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]; (7R)-7-Amino-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[[(5-Methyl-1,3,4-thiadiazole-2-yl)thio]methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-Amino-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid (Cefazolin Impurity); 7-amino-3-(5'-methyl-1',3',4'-thiadiazol-2'-ylthiomethyl)cephalosporanic acid; TIANFU-CHEM - 7-AMINO-3-[(5-METHYL-1,3,4-THIADIAZOL-2-YL)THIOMETHYL]CHALOSPHORANIC ACID; Cefazolin Impurity 7 CRS（Cefazolin Impurity A CRS）; 7-Amino-3-[[(5-methyl-1,3,4-thiadiazol-2yl)thiomethyl]-3-chalosporanicacid; 7-Amino-3-[(5-methyl-1,3,4-thiadiazol-2-yl)-thiomethyl]-cephalosporanic aci; 7-Amino-3-([5-methyl-1,3,4-thiadiazol-2-yl] thiomethyl)-3-chem-4-cboxylic acid; Cefuroxime nucleus (7-TDA); Cefazolin Sodium Impurity A; 7-Amino-3-[(5-methyl-1,3,4-thiadiazol-2-yl)-thiomethyl]-chalosporanic aci

物化性质

• 密度: 1.7±0.1 g/cm3
• 沸点: 678.2±65.0 °C at 760 mmHg
• 分子式: C₁₁H₁₂N₄O₃S₃
• 分子量: 344.433
• 闪点: 364.0±34.3 °C
• 精确质量: 344.007141
• PSA: 188.25000
• LogP: 0.42
• 蒸汽压: 0.0±2.2 mmHg at 25°C
• 折射率: 1.769
• 储存条件: 室温，干燥

合成路线

111389-99-2 29490-19-5 ~% 30246-33-4

文献：Journal of Organic Chemistry, , vol. 53, # 5 p. 983 - 991

29490-19-5 957-68-6 ~86% 30246-33-4

文献：Saikawa; Takano; Momonoi; et al. Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 12 p. 5534 - 5538

111390-00-2 ~% 30246-33-4

文献：Journal of Organic Chemistry, , vol. 53, # 5 p. 983 - 991

31461-04-8 ~% 30246-33-4

文献：Journal of Organic Chemistry, , vol. 53, # 5 p. 983 - 991

106134-67-2 29490-19-5 ~% 30246-33-4

文献：Journal of Organic Chemistry, , vol. 53, # 5 p. 983 - 991

98493-37-9 ~% 30246-33-4

文献：Tetrahedron, , vol. 41, # 22 p. 5133 - 5139

上下游产品

上游产品  6
111389-99-2 29490-19-5 957-68-6 111390-00-2
106134-67-2 98493-37-9
下游产品  3
56187-47-4 25953-19-9 21732-17-2